A unique squalenoylated and nonpegylateddoxorubicin nanomedicine with systemiclong-circulating properties and anticancer activity

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 2, 2014, Pages

  Maksimenko, Andrei ^a   Dosio, Franco ^b   Mougin, Julie ^a   Ferrero, Annalisa ^b   Wack, Severine ^a   Reddy, L Harivardhan ^a   Weyn, Andree Anne ^c   Lepeltier, Elise ^a   Bourgaux, Claudie ^a   Stella, Barbara ^b   Cattel, Luigi ^b   Couvreur, Patrick ^a  

^a UNIV PARIS SUD   (France)

^b UNIVERSITY OF TURIN   (Italy)

^c Centre de Recherches Biologiques   (France)

Author keywords

Lung cancer; Pancreatic cancer; Squalene doxorubicin bioconjugate

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; DOXORUBICIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; SQUALENE; SQUALENOYL DOXORUBICIN; UNCLASSIFIED DRUG; TROPONIN T;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS ASSAY; AREA UNDER THE CURVE; ARTICLE; BIOSYNTHESIS; BODY WEIGHT; CARDIOTOXICITY; CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG STRUCTURE; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUNG CANCER; MAXIMUM TOLERATED DOSE; MOUSE; NANOMEDICINE; NONHUMAN; PANCREAS CANCER; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION; TUMOR VOLUME; ANALYSIS OF VARIANCE; ANIMAL; APOPTOSIS; BLOOD; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; CRYOELECTRON MICROSCOPY; DRUG EFFECT; FLUORESCENCE; HEART; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOLOGY; MALE; METABOLISM; METHODOLOGY; NUDE MOUSE; PHYSIOLOGY; SQUALENE-DOXORUBICIN BIOCONJUGATE; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL LINE; WESTERN BLOTTING;

LUNG CANCER; PANCREATIC CANCER; SQUALENE-DOXORUBICIN BIOCONJUGATE;

ANALYSIS OF VARIANCE; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRYOELECTRON MICROSCOPY; DOXORUBICIN; FEMALE; FLUORESCENCE; HEART; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; MICROSCOPY, ELECTRON, TRANSMISSION; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; NANOMEDICINE; RATS; SQUALENE; TROPONIN T;

EID: 84892561611     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1313459110     Document Type: Article

References (40)

1. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D (1999) Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51(4):691-743.
2. Brannon-Peppas L, Blanchette JO (2004) Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 56(11):1649-1659.
3. Duncan R (2006) Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 6(9):688-701.
4. Lee CC, MacKay JA, Fréchet JM, Szoka FC (2005) Designing dendrimers for biological applications. Nat Biotechnol 23(12):1517-1526.
5. Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46(12 Pt 1):6387-6392.
6. Couvreur P, et al. (2006) Squalenoyl nanomedicines as potential therapeutics. Nano Lett 6(11):2544-2548.
7. American Cancer Society (2011) Doxorubicin. Available at www.cancer.org/Treatment/TreatmentsandSideEffects/GuidetoCancerDrugs/ doxorubicin Accessed December 12, 2013.
8. Pfizer Inc. (2011) Doxorubicin Hydrochloride for Injection. Available at http://labeling. pfizer.com/ShowLabeling.aspx?id=530. Accessed December 12, 2013.
9. National Cancer Institute (2013) Cancer Drug Information: Doxorubicin Hydrochloride. Available at www.cancer.gov/cancertopics/druginfo/ doxorubicinhydrochloride. Accessed December 12, 2013.
10. Herman EH, el-Hage AN, Ferrans VJ, Ardalan B (1985) Comparison of the severity of the chronic cardiotoxicity produced by doxorubicin in normotensive and hypertensive rats. Toxicol Appl Pharmacol 78(2):202-214.
11. Jain A, et al. (2010) Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug. J Control Release 148(3):359-367.
12. Liu D, et al. (2011) Drug pH-sensitive release in vitro and targeting ability of polyamidoamine dendrimer complexes for tumor cells. Chem Pharm Bull (Tokyo) 59(1): 63-71.
13. Gabizon A, et al. (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54(4):987-992.
14. Gao ZG, Lee DH, Kim DI, Bae YH (2005) Doxorubicin loaded pH-sensitive micelle targeting acidic extracellular pH of human ovarian A2780 tumor in mice. J Drug Target 13(7):391-397.
15. Licciardi M, Cavallaro G, Di Stefano M, Fiorica C, Giammona G (2011) Polyaspartamide- graft-polymethacrylate nanoparticles for doxorubicin delivery. Macromol Biosci 11(3):445-454.
16. O?Brien ME, et al.; CAELYX Breast Cancer Study Group (2004) Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15(3):440-449.
17. Immordino ML, Dosio F, Cattel L (2006) Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 1(3): 297-315.
18. Ogawara K-I, Un K, Tanaka K-I, Higaki K, Kimura T (2009) In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells. J Control Release 133(1):4-10.
19. Lorusso D, et al. (2007) Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (?hand-foot? syndrome). Ann Oncol 18(7):1159-1164.
20. von Moos R, et al. (2008) Pegylated liposomal doxorubicin-associated hand-foot syndrome: Recommendations of an international panel of experts. Eur J Cancer 44(6): 781-790.
21. Hamad I, Hunter AC, Szebeni J, Moghimi SM (2008) Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Mol Immunol 46(2):225-232.
22. Szebeni J, et al. (2006) Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function. Am J Physiol Heart Circ Physiol 290(3):H1050-H1058.
23. Ishida T, et al. (2006) Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J Control Release 112(1):15-25.
24. Dams ET, et al. (2000) Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J Pharmacol Exp Ther 292(3): 1071-1079.
25. Dos Santos N, et al. (2004) pH gradient loading of anthracyclines into cholesterol-free liposomes: Enhancing drug loading rates through use of ethanol. Biochim Biophys Acta 1661(1):47-60.
26. Gardikis K, Tsimplouli C, Dimas K, Micha-Screttas M, Demetzos C (2010) New chimeric advanced Drug Delivery nano Systems (chi-aDDnSs) as doxorubicin carriers. Int J Pharm 402(1-2):231-237.
27. Yadav AK, et al. (2008) Preparation and characterization of HA-PEG-PCL intelligent core-corona nanoparticles for delivery of doxorubicin. J Drug Target 16(6):464-478.
28. Patri AK, Kukowska-Latallo JF, Baker JR, Jr. (2005) Targeted drug delivery with dendrimers: Comparison of the release kinetics of covalently conjugated drug and noncovalent drug inclusion complex. Adv Drug Deliv Rev 57(15):2203-2214.
29. Boucher C, Gobeil S, Samejima K, Earnshaw WC, Poirier GG (2001) Identification and analysis of caspase substrates: Proteolytic cleavage of poly(ADP-ribose)polymerase and DNA fragmentation factor 45. Methods Cell Biol 66:289-306.
30. Koh E, Nakamura T, Takahashi H (2004) Troponin-T and brain natriuretic peptide as predictors for adriamycin-induced cardiomyopathy in rats. Circ J 68(2):163-167.
31. Singal PK, Iliskovic N (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med 339(13):900-905.
32. Myers CE, et al. (1977) Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 197(4299):165-167.
33. Abraham SA, et al. (2005) The liposomal formulation of doxorubicin. Methods Enzymol 391:71-97.
34. Chen Y, Bathula SR, Li J, Huang L (2010) Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J Biol Chem 285(29):22639-22650.
35. Gardikis K, et al. (2010) New drug delivery nanosystem combining liposomal and dendrimeric technology (liposomal locked-in dendrimers) for cancer therapy. J Pharm Sci 99(8):3561-3571.
36. Ishihara T, et al. (2009) Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles. Pharm Res 26(10):2270-2279.
37. Szepeshazi K, et al. (2001) Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers. Clin Cancer Res 7(9):2854-2861.
38. Geng Y, et al. (2007) Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol 2(4):249-255.
39. Christian DA, et al. (2009) Flexible filaments for in vivo imaging and delivery: Persistent circulation of filomicelles opens the dosage window for sustained tumor shrinkage. Mol Pharm 6(5):1343-1352.
40. Wiedemeyer R, Westermann F, Wittke I, Nowock J, Schwab M (2003) Ataxin-2 promotes apoptosis of human neuroblastoma cells. Oncogene 22(3):401-411.